D
Bristol-Myers Squibb Company
BMY
$59.01
-$1.27-2.11%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
P/E (TTM)
--
EPS (TTM)
D
Sell
11/19/2024Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to D+ from D on 11/19/2024 due to an increase in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was upgraded to D+ from D on 11/19/2024 due to an increase in the volatility index and total return index.
D
Sell
11/4/2024Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to D from D+ on 11/4/2024 due to a noticeable decline in the efficiency index and dividend index. Net income declined 27.92% from $1.68B to $1.21B, and total capital declined 3.43% from $71.07B to $68.64B.
Bristol-Myers Squibb Company (BMY) was downgraded to D from D+ on 11/4/2024 due to a noticeable decline in the efficiency index and dividend index. Net income declined 27.92% from $1.68B to $1.21B, and total capital declined 3.43% from $71.07B to $68.64B.
D
Sell
4/26/2024Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to D+ from C- on 4/26/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.8672 to -$5.89, net income declined 775.99% from $1.76B to -$11.91B, and operating cash flow declined 33.35% from $4.25B to $2.83B.
Bristol-Myers Squibb Company (BMY) was downgraded to D+ from C- on 4/26/2024 due to a significant decline in the valuation index, growth index and efficiency index. Earnings per share declined from $0.8672 to -$5.89, net income declined 775.99% from $1.76B to -$11.91B, and operating cash flow declined 33.35% from $4.25B to $2.83B.
C
Hold
10/31/2023Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 10/31/2023 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.18 to 0.99, and debt to equity increased from 1.18 to 1.3.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 10/31/2023 due to a noticeable decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.18 to 0.99, and debt to equity increased from 1.18 to 1.3.
C
Hold
7/27/2023Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 7/27/2023 due to a decline in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 7/27/2023 due to a decline in the volatility index and total return index.
C
Hold
7/3/2023Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 7/3/2023 due to a decline in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 7/3/2023 due to a decline in the total return index and volatility index.
B
Buy
6/16/2023Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 6/16/2023 due to an increase in the total return index and valuation index.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 6/16/2023 due to an increase in the total return index and valuation index.
C
Hold
5/30/2023Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 5/30/2023 due to a decline in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 5/30/2023 due to a decline in the total return index and volatility index.
B
Buy
2/28/2023Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 2/28/2023 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 26.95% from $2.43B to $1.77B, operating cash flow declined 10.33% from $3.69B to $3.31B, and the quick ratio declined from 1.18 to 1.06.
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 2/28/2023 due to a major decline in the growth index, valuation index and solvency index. EBIT declined 26.95% from $2.43B to $1.77B, operating cash flow declined 10.33% from $3.69B to $3.31B, and the quick ratio declined from 1.18 to 1.06.
B
Buy
2/25/2022Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 2/25/2022 due to an increase in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 2/25/2022 due to an increase in the total return index and volatility index.
B
Buy
2/11/2022Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C- on 2/11/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.69 to $1.0751, net income increased 53.43% from $1.55B to $2.37B, and total revenue increased 3.11% from $11.62B to $11.99B.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C- on 2/11/2022 due to a significant increase in the growth index, valuation index and efficiency index. Earnings per share increased from $0.69 to $1.0751, net income increased 53.43% from $1.55B to $2.37B, and total revenue increased 3.11% from $11.62B to $11.99B.
C
Hold
11/19/2021Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 11/19/2021 due to a decline in the volatility index, total return index and valuation index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 11/19/2021 due to a decline in the volatility index, total return index and valuation index.
C
Hold
11/4/2021Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 11/4/2021 due to an increase in the volatility index, total return index and valuation index.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 11/4/2021 due to an increase in the volatility index, total return index and valuation index.
C
Hold
9/21/2021Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 9/21/2021 due to a decline in the volatility index, valuation index and efficiency index. Net income declined 47.8% from $2.02B to $1.06B, and total capital declined 2.09% from $84.94B to $83.17B.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 9/21/2021 due to a decline in the volatility index, valuation index and efficiency index. Net income declined 47.8% from $2.02B to $1.06B, and total capital declined 2.09% from $84.94B to $83.17B.
C
Hold
3/22/2021Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 3/22/2021 due to an increase in the volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 3/22/2021 due to an increase in the volatility index.
C
Hold
2/16/2021Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 2/16/2021 due to a noticeable decline in the efficiency index, solvency index and total return index. Net income declined 635.63% from $1.87B to -$10.03B, debt to equity increased from 0.9 to 1.34, and the quick ratio declined from 1.43 to 1.31.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 2/16/2021 due to a noticeable decline in the efficiency index, solvency index and total return index. Net income declined 635.63% from $1.87B to -$10.03B, debt to equity increased from 0.9 to 1.34, and the quick ratio declined from 1.43 to 1.31.
C
Hold
11/9/2020Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 11/9/2020 due to an increase in the volatility index and efficiency index. Net income increased 2,302.35% from -$85M to $1.87B.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 11/9/2020 due to an increase in the volatility index and efficiency index. Net income increased 2,302.35% from -$85M to $1.87B.
C
Hold
10/27/2020Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 10/27/2020 due to a decline in the total return index, volatility index and dividend index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 10/27/2020 due to a decline in the total return index, volatility index and dividend index.
C
Hold
10/8/2020Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 10/8/2020 due to an increase in the volatility index and dividend index.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 10/8/2020 due to an increase in the volatility index and dividend index.
C
Hold
9/10/2020Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 9/10/2020 due to a decline in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 9/10/2020 due to a decline in the volatility index and total return index.
C
Hold
8/26/2020Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 8/26/2020 due to an increase in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 8/26/2020 due to an increase in the total return index and volatility index.
C
Hold
8/7/2020Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 8/7/2020 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 17.03% from $2.36B to $1.96B, and total revenue declined 6.05% from $10.78B to $10.13B.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 8/7/2020 due to a large decline in the growth index, volatility index and valuation index. EBIT declined 17.03% from $2.36B to $1.96B, and total revenue declined 6.05% from $10.78B to $10.13B.
C
Hold
5/8/2020Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 5/8/2020 due to a major decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.91 to 0.94.
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 5/8/2020 due to a major decline in the valuation index, total return index and solvency index. Debt to equity increased from 0.91 to 0.94.
C
Hold
2/26/2020Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B on 2/26/2020 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 178.05% from $1.35B to -$1.06B, earnings per share declined from $0.829 to -$0.5516, and EBIT declined 23.31% from $1.81B to $1.39B.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B on 2/26/2020 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 178.05% from $1.35B to -$1.06B, earnings per share declined from $0.829 to -$0.5516, and EBIT declined 23.31% from $1.81B to $1.39B.
B
Buy
2/5/2020Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 2/5/2020 due to an increase in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 2/5/2020 due to an increase in the total return index and volatility index.
B
Buy
12/19/2019Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 12/19/2019 due to a noticeable increase in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 12/19/2019 due to a noticeable increase in the total return index and volatility index.
C
Hold
12/6/2019Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 12/6/2019 due to a large increase in the volatility index, efficiency index and total return index. Total capital increased 3.75% from $41.95B to $43.53B.
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 12/6/2019 due to a large increase in the volatility index, efficiency index and total return index. Total capital increased 3.75% from $41.95B to $43.53B.
C
Hold
9/20/2019Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 9/20/2019 due to an increase in the valuation index, total return index and growth index. Operating cash flow increased 49.86% from $1.39B to $2.08B, EBIT increased 35.6% from $1.74B to $2.36B, and total revenue increased 5.96% from $5.92B to $6.27B.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 9/20/2019 due to an increase in the valuation index, total return index and growth index. Operating cash flow increased 49.86% from $1.39B to $2.08B, EBIT increased 35.6% from $1.74B to $2.36B, and total revenue increased 5.96% from $5.92B to $6.27B.
C
Hold
5/17/2019Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 5/17/2019 due to a decline in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 5/17/2019 due to a decline in the volatility index and total return index.
C
Hold
2/27/2019Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 2/27/2019 due to a significant increase in the valuation index, growth index and solvency index. Operating cash flow increased 89.91% from $1.28B to $2.43B, total revenue increased 4.96% from $5.69B to $5.97B, and the quick ratio increased from 1.31 to 1.38.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 2/27/2019 due to a significant increase in the valuation index, growth index and solvency index. Operating cash flow increased 89.91% from $1.28B to $2.43B, total revenue increased 4.96% from $5.69B to $5.97B, and the quick ratio increased from 1.31 to 1.38.
C
Hold
1/3/2019Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 1/3/2019 due to a decline in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 1/3/2019 due to a decline in the total return index and volatility index.
C
Hold
10/29/2018Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 10/29/2018 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 409.65% from $373M to $1.9B, earnings per share increased from $0.2284 to $1.16, and operating cash flow increased 21% from $1.06B to $1.28B.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 10/29/2018 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 409.65% from $373M to $1.9B, earnings per share increased from $0.2284 to $1.16, and operating cash flow increased 21% from $1.06B to $1.28B.
C
Hold
8/16/2018Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C- from D+ on 8/16/2018 due to an increase in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was upgraded to C- from D+ on 8/16/2018 due to an increase in the total return index and volatility index.
D
Sell
7/27/2018Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to D+ from C- on 7/27/2018 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.91 to $0.2284, and operating cash flow declined 10.04% from $1.18B to $1.06B.
Bristol-Myers Squibb Company (BMY) was downgraded to D+ from C- on 7/27/2018 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $0.91 to $0.2284, and operating cash flow declined 10.04% from $1.18B to $1.06B.
C
Hold
5/15/2018Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 5/15/2018 due to a decline in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 5/15/2018 due to a decline in the volatility index and total return index.
C
Hold
4/30/2018Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 4/30/2018 due to a noticeable increase in the growth index, solvency index and dividend index. Earnings per share increased from -$1.4284 to $0.91, EBIT increased 33.54% from $1.1B to $1.47B, and debt to equity declined from 0.68 to 0.6.
Bristol-Myers Squibb Company (BMY) was upgraded to C from C- on 4/30/2018 due to a noticeable increase in the growth index, solvency index and dividend index. Earnings per share increased from -$1.4284 to $0.91, EBIT increased 33.54% from $1.1B to $1.47B, and debt to equity declined from 0.68 to 0.6.
C
Hold
4/16/2018Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 4/16/2018 due to a decline in the volatility index and solvency index.
Bristol-Myers Squibb Company (BMY) was downgraded to C- from C on 4/16/2018 due to a decline in the volatility index and solvency index.
C
Hold
2/15/2018Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 2/15/2018 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.51 to -$1.4284, operating cash flow declined 34.79% from $1.71B to $1.12B, and EBIT declined 19.31% from $1.37B to $1.1B.
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 2/15/2018 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.51 to -$1.4284, operating cash flow declined 34.79% from $1.71B to $1.12B, and EBIT declined 19.31% from $1.37B to $1.1B.
C
Hold
2/5/2018Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 2/5/2018 due to a decline in the volatility index, total return index and valuation index.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 2/5/2018 due to a decline in the volatility index, total return index and valuation index.
B
Buy
12/27/2017Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 12/27/2017 due to a decline in the total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 12/27/2017 due to a decline in the total return index.
B
Buy
12/11/2017Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 12/11/2017 due to a noticeable increase in the total return index and growth index. Operating cash flow increased 8.14% from $1.58B to $1.71B, and total revenue increased 2.14% from $5.14B to $5.25B.
Bristol-Myers Squibb Company (BMY) was upgraded to B from B- on 12/11/2017 due to a noticeable increase in the total return index and growth index. Operating cash flow increased 8.14% from $1.58B to $1.71B, and total revenue increased 2.14% from $5.14B to $5.25B.
B
Buy
9/28/2017Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 9/28/2017 due to an increase in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 9/28/2017 due to an increase in the volatility index and total return index.
C
Hold
8/3/2017Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 8/3/2017 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 83.97% from $861M to $1.58B, and total revenue increased 4.36% from $4.93B to $5.14B.
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 8/3/2017 due to a significant increase in the growth index, valuation index and volatility index. Operating cash flow increased 83.97% from $861M to $1.58B, and total revenue increased 4.36% from $4.93B to $5.14B.
C
Hold
10/6/2016Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 10/6/2016 due to a noticeable decline in the volatility index.
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 10/6/2016 due to a noticeable decline in the volatility index.
C
Hold
9/21/2016Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 9/21/2016 due to a noticeable decline in the volatility index and total return index.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 9/21/2016 due to a noticeable decline in the volatility index and total return index.
B
Buy
8/24/2016Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 8/24/2016 due to a significant decline in the total return index and volatility index.
Bristol-Myers Squibb Company (BMY) was downgraded to B- from B on 8/24/2016 due to a significant decline in the total return index and volatility index.
B
Buy
7/29/2016Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B from C+ on 7/29/2016 due to a significant increase in the total return index, valuation index and growth index. Operating cash flow increased 206.48% from -$386M to $411M, total revenue increased 10.93% from $4.39B to $4.87B, and EBIT increased 2.27% from $1.54B to $1.58B.
Bristol-Myers Squibb Company (BMY) was upgraded to B from C+ on 7/29/2016 due to a significant increase in the total return index, valuation index and growth index. Operating cash flow increased 206.48% from -$386M to $411M, total revenue increased 10.93% from $4.39B to $4.87B, and EBIT increased 2.27% from $1.54B to $1.58B.
C
Hold
5/10/2016Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 5/10/2016 due to an increase in the growth index, total return index and efficiency index. Net income increased 706.6% from -$197M to $1.2B, earnings per share increased from -$0.1195 to $0.71, and EBIT increased 85.35% from $833M to $1.54B.
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 5/10/2016 due to an increase in the growth index, total return index and efficiency index. Net income increased 706.6% from -$197M to $1.2B, earnings per share increased from -$0.1195 to $0.71, and EBIT increased 85.35% from $833M to $1.54B.
C
Hold
3/10/2016Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 3/10/2016 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.42 to -$0.1195, the quick ratio declined from 1.28 to 1.05, and EBIT declined 5.13% from $878M to $833M.
Bristol-Myers Squibb Company (BMY) was downgraded to C from C+ on 3/10/2016 due to a decline in the growth index, solvency index and valuation index. Earnings per share declined from $0.42 to -$0.1195, the quick ratio declined from 1.28 to 1.05, and EBIT declined 5.13% from $878M to $833M.
C
Hold
10/29/2015Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 10/29/2015 due to a large increase in the growth index, efficiency index and solvency index. Operating cash flow increased 638.03% from $71M to $524M, the quick ratio increased from 1.21 to 1.28, and debt to equity declined from 0.49 to 0.48.
Bristol-Myers Squibb Company (BMY) was upgraded to C+ from C on 10/29/2015 due to a large increase in the growth index, efficiency index and solvency index. Operating cash flow increased 638.03% from $71M to $524M, the quick ratio increased from 1.21 to 1.28, and debt to equity declined from 0.49 to 0.48.
C
Hold
7/24/2015Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from B- on 7/24/2015 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.71 to -$0.08, operating cash flow declined 88.66% from $626M to $71M, and EBIT declined 21.4% from $1.35B to $1.06B.
Bristol-Myers Squibb Company (BMY) was downgraded to C from B- on 7/24/2015 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.71 to -$0.08, operating cash flow declined 88.66% from $626M to $71M, and EBIT declined 21.4% from $1.35B to $1.06B.
B
Buy
7/22/2015Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 7/22/2015 due to an increase in the total return index.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C+ on 7/22/2015 due to an increase in the total return index.
C
Hold
7/7/2015Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 7/7/2015 due to a noticeable decline in the volatility index, total return index and growth index.
Bristol-Myers Squibb Company (BMY) was downgraded to C+ from B- on 7/7/2015 due to a noticeable decline in the volatility index, total return index and growth index.
B
Buy
4/29/2015Upgraded
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C on 4/29/2015 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0078 to $0.71, EBIT increased 166.67% from $543M to $1.45B, and operating cash flow increased 9.44% from $572M to $626M.
Bristol-Myers Squibb Company (BMY) was upgraded to B- from C on 4/29/2015 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from $0.0078 to $0.71, EBIT increased 166.67% from $543M to $1.45B, and operating cash flow increased 9.44% from $572M to $626M.
C
Hold
2/13/2015Downgrade
Bristol-Myers Squibb Company (BMY) was downgraded to C from B on 2/13/2015 due to a substantial decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.43 to $0.0078, EBIT declined 51.94% from $930M to $447M, and operating cash flow declined 36.66% from $903M to $572M.
Bristol-Myers Squibb Company (BMY) was downgraded to C from B on 2/13/2015 due to a substantial decline in the valuation index, growth index and dividend index. Earnings per share declined from $0.43 to $0.0078, EBIT declined 51.94% from $930M to $447M, and operating cash flow declined 36.66% from $903M to $572M.
NYSE
03/14/2025 4:00PM Eastern
Quotes delayed
